🌍💪 Amidst turbulence, it is important not to forget our progress as a species! 🚀 During the last century, basic sanitation improved, child mortality reduced, and GDP soared worldwide! 📈 Science's role is paramount in our advancements, and safeguarding its freedom is crucial.
Let's stand united against misinformation and bad scientific practices to keep the journey of progress going strong! 🌐🔒 #ScienceMatters #Progress #Humanity
Article in JAMA on how over-diagnosis of autism is increasing and becomes 'a self fulfilling prophecy' and 'does not allow a child to develop their full capacity'. https://t.co/htVXJreiAk.
This study confirms (or is at least in line with) the idea that if you compare psychotherapies in a study with similar dose and duration of intervention that they all work about the same. Comparing a psychotherapy to "wait list control" is so biased that it should be illegal!
Across the social sciences, half of research doesn’t replicate: Ambitious effort tested whether more than 100 papers held up on multiple types of “repeatability” tests via @JeffreyBrainard
https://t.co/4y8aJ7sMAp
Half of social-science studies fail replication test in years-long project: Results from massive, ‘eagerly awaited’ initiative reinforce concerns about the credibility of science but raise hope for solutions. https://t.co/mcYb97OH7Q via @nicolakimjones
Our new paper in Nature Mental Health - why everyone treated with clozapine should be offered ACKR1 testing to identify individuals with benign neutropenia who can safely continue clozapine therapy.
https://t.co/u9mc24DIqz
ECT is by far most effective/safest/fastest treatment for depressions that are: 1)very severe; 2)psychotic; or 3)unresponsive to meds.
Underused because of: 1)stigma; 2)misinformation campaigns; 3)poor access; 4)inconvenience; 5)neglect in training
See why my 1st choice for me:
Swedish authorities are considering requests for “de-diagnosis services” for autism and ADHD from a new patient group: adults who no longer want their diagnosis
https://t.co/31BOnTb3nl
Viewpoint: Patients with psychotic conditions often wish to stop antipsychotics, suggesting a shift to shared deliberation for collaborative management of associated risks. https://t.co/adUvZDfVUV
"While several medications [for child obesity] demonstrated greater weight loss than placebo, the totality of the evidence was found to be inadequate. An important limitation of the pharmacotherapy studies was that there was only a single trial for each effective medication (ie, phentermine/topiramate, semaglutide, and liraglutide) that lasted longer than 2 months." https://t.co/fEqYmAVNK5
Esketamine nasal spray as a monotherapy improved depressive symptoms in treatment-resistant depression (TRD) compared to placebo. https://t.co/qTTQmTerKA
Only 10-30% with bipolar take lithium, but 90% of experts in new survey rank it their top choice:
https://t.co/CQq2VAzOJW
Why? Better long-term outcomes, and addresses underlying causes of the disorder in new review by R Post et al:
https://t.co/CQq2VAzOJW
Viewpoint: Target trial emulation can improve observational study validity by applying randomized trial design principles, but it is not a substitute for randomization.
https://t.co/nMtfMxA7tG
Anti-psychiatry has plenty of brilliant minds who can tear the field apart with philosophy, rhetoric, and clever arguments. But none of that survives a single shift in a psych ER.